Category Biodiversity/Genetic Resources/Biotech

Promotion: Upcoming Courses And Events Provide Insights Into IP

Informa has announced a range of upcoming events and courses on the essential aspects of intellectual property and technology of interest to Intellectual Property Watch readers. Here is the list:

Events:

IP Dispute Resolution - 28 - 29 June 2012, Grange City Hotel, London, UK

European Trademarks 2012 – 3rd July 2012, Grange City Hotel, London, UK

Protecting Corporate Information – 5th July 2012, One Drummond Gate, London, UK

IT Law Summer School 2012 – 30 July - 3 August 2012, Downing College, Cambridge, UK

IP Summer School - 13 - 17 August 2012, Downing College, Cambridge, UK

Distance Learning Courses:

Computer and Communications Law LLM, PgDip - from Queen Mary, University of London

UK, EU & US Copyright Law LLM, PgDip - from King's College London

US Licensing Experts: Innovation Is Still Happening, Let’s Help It Along

BOSTON - Early stage innovation is still strong in the United States, but parties need to work better together and address bottlenecks in the middle stages, a panel of university and private sector experts said this week. Meanwhile, the president of global biotechnology company Genzyme said the industry is not in crisis and the company is hopeful about its recent merger with Sanofi.

Medicines Patent Pool Director Ellen ‘t Hoen To Leave Next Month

Executive Director Ellen 't Hoen is departing the Medicines Patent Pool, the cutting edge UN spin-off project that works to lower prices on and stimulate new development of HIV medicines and other products through negotiating voluntary licence agreements. According to a release, 't Hoen has fulfilled the mission of guiding the organisation from a startup onto "firm footing" and has informed the Board that she will leave on 1 May.

US Supreme Court Edges Toward Reviewing Extent Of GMO Patents

It’s unclear if the US Supreme Court wants to address yet another controversial issue in patent law, but on 2 April, the court took a small step in that direction. That’s when the court formally asked the US Justice Department to opine on whether the high court should grant certiorari in Bowman v. Monsanto Co.